Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can potentially ameliorate ineffective hematopoiesis and address cytopenias, and also provide broader ...
Regeneron (REGN) announced new and updated data for odronextamab were presented at the 66th American Society of Hematology, or ASH, annual ...
Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) ...
AFM28, a bispecific, tetravalent innate cell engager (ICE ®) targeting CD123 and CD16A, achieved a 40% composite complete ...
Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...
Cogent Biosciences' SUMMIT trial shows bezuclastinib improves symptoms and quality of life in systemic mastocytosis, with ...
The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...
The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...
Bionomics (BNOX) announced that the results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also ...
Kura Oncology, Inc. (Nasdaq: KURA, "Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin”) provided encouraging cli ...
The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...
A subgroup analysis showed that epcoritamab is effective regardless of CAR T–exposure in patients with R/R LBCL.